New drugs for breast cancer

Lancet

Volumn 360, Issue 9335, 2002, Pages 790-792

  Smith, Ian E ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE; CAPECITABINE; CLODRONIC ACID; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EXEMESTANE; FULVESTRANT; GOSERELIN; IBANDRONIC ACID; LETROZOLE; NAVELBINE; PACLITAXEL; PAMIDRONIC ACID; TAMOXIFEN; TOREMIFENE; TRASTUZUMAB; ZOLEDRONIC ACID;

ARTHRALGIA; BREAST CANCER; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; FEVER; HAND FOOT SYNDROME; HUMAN; MYALGIA; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; SHORT SURVEY; STOMATITIS; TOXICITY; VOMITING;

EID: 0037036949     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)09903-8     Document Type: Short Survey

References (24)

1. O'Shaughnessy J., Miles D., Vukelja S., et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol. 20:2002;2812-2823.
2. Chan S., Friedrichs K., Noel D., et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer: the 303 Study Group. J Clin Oncol. 17:1999;2341-2354.
3. Nabholtz J-M, Pienkowski T, Mackey J, et al. Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophophamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer (BC) patients: interim analysis of the BCIRG 001 study. Proc ASCO 2002; 21: 141 (abstr).
4. Biganzoli L., Cufer T., Bruning P.F., et al. Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: the European Organization for Research and Treatment of Cancer 10961 multicenter phase III trial. J Clin Oncol. 20:2002;3114-3121.
5. Henderson IC, Berry D, Demetri G, et al. Improved disease-free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (pts) with node-positive primary breast cancer (BC). Proc ASCO 1998; 17: 101 (abstr).
6. Goldhirsch A., Glick J.H., Gelber R.D., Coates A.S., Senn H.J. Meeting highlights: international consensus panel on the treatment of primary breast cancer. Seventh international conference on adjuvant therapy of primary breast cancer. J Clin Oncol. 19:2001;3817-3827.
7. Blum J.L., Jones S.E., Buzdar A.U., et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol. 17:1999;485-493.
8. Hamilton A., Piccart M. The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer. Ann Oncol. 10:1999;377-384.
9. Mouridsen H., Gershanovich M., Sun Y., et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol. 19:2001;2596-2606.
10. Nabholtz J.M., Buzdar A., Pollak M., et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast carcinoma in postmenopausal women: results of a North American multicenter randomized trial. J Clin Oncol. 18:2000;3758-3767.
11. Bonneterre J., Thurlimann B., Robertson J.F.R., et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study. J Clin Oncol. 18:2000;3748-3757.
12. Eiermann W., Paepke S., Apffelstaedt J., et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol. 12:2001;1527-1532.
13. Ellis M.J., Coop A., Singh B., et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol. 19:2001;3808-3816.
14. ATAC Trialists Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 359:2002;2131-2139.
15. Klign J.G.M., Beex L.V.A.M., Maruriac L., et al. Combined treatment with buserelin and tamoxifen in premenopusal metastatic breast cancer: a randomized study. J Natl Cancer Inst. 92:2000;903-911.
16. Klign J.G.M., Blarney R.W., Baccardo F., Tominaga T., Duchateau L., Sylvester R. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol. 19:2001;335-343.
17. Howell A., DeFriend D., Robertson J., Blamey R., Walton P. Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet. 345:1995;29-30.
18. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 344:2001;783-792.
19. Burstein H.J., Kuter I., Campos S.M., et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol. 19:2001;2722-2730.
20. Vogel C.L., Cobleigh M.A., Tripathy D., et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 20:2002;719-726.
21. Coleman R.E. Should bisphosphonates be the treatment of choice for metastatic bone disease? Semin Oncol. 28:(suppl 11):2001;35-41.
22. Diel I.J., Solomayer E.F., Costa S.D., et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med. 339:1998;357-363.
23. Saarto T., Blomqvist C., Virkkunen P., Elomaa I. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol. 19:2001;10-17.
24. Powles T., Paterson S., Kanis J.A., et al. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol. 20:2002;3124-3129.